Identification of an antimalarial synthetic trioxolane drug development candidate
Language: 
English
Abstract: 

The discovery of artemisinin more than 30 years ago provided a completely new antimalarial structural prototype; that is, a molecule with a pharmacophoric peroxide bond in a unique 1,2,4-trioxane heterocycle. Available evidence suggests that artemisinin and related peroxidic antimalarial drugs exert their parasiticidal activity subsequent to reductive activation by haem, released as a result of haemoglobin digestion by the malaria-causing parasite. This irreversible redox reaction produces carbon-centred free radicals, leading to alkylation of haem and proteins (enzymes), one of which--the sarcoplasmic-endoplasmic reticulum ATPase PfATP6 (ref. 7)--may be critical to parasite survival. Notably, there is no evidence of drug resistance to any member of the artemisinin family of drugs. The chemotherapy of malaria has benefited greatly from the semi-synthetic artemisinins artemether and artesunate as they rapidly reduce parasite burden, have good therapeutic indices and provide for successful treatment outcomes. However, as a drug class, the artemisinins suffer from chemical (semi-synthetic availability, purity and cost), biopharmaceutical (poor bioavailability and limiting pharmacokinetics) and treatment (non-compliance with long treatment regimens and recrudescence) issues that limit their therapeutic potential. Here we describe how a synthetic peroxide antimalarial drug development candidate was identified in a collaborative drug discovery project.

Author(s): 
Vennerstrom, Jonathan L.
Arbe-Barnes, Sarah
Brun, Reto
Charman, Susan A.
Chiu, Francis C. K.
Chollet, Jacques
Dong, Yuxiang
Dorn, Arnulf
Hunziker, Daniel
Matile, Hugues
McIntosh, Kylie
Padmanilayam, Maniyan
Santo Tomas, Josefina
Scheurer, Christian
Scorneaux, Bernard
Tang, Yuanqing
Urwyler, Heinrich
Wittlin, Sergio
Charman, William N.
Item Type: 
Journal Article
Publication Title: 
Nature
Journal Abbreviation: 
Nature
Publication Date: 
8/19/2004
Publication Year: 
2004
Pages: 
900-904
Volume: 
430
Issue: 
7002
ISSN: 
1476-4687
DOI: 
10.1038/nature02779
Library Catalog: 
PubMed
Extra: 
PMID: 15318224

Turabian/Chicago Citation

Jonathan L. Vennerstrom, Sarah Arbe-Barnes, Reto Brun, Susan A. Charman, Francis C. K. Chiu, Jacques Chollet, Yuxiang Dong, Arnulf Dorn, Daniel Hunziker, Hugues Matile, Kylie McIntosh, Maniyan Padmanilayam, Josefina Santo Tomas, Christian Scheurer, Bernard Scorneaux, Yuanqing Tang, Heinrich Urwyler, Sergio Wittlin and William N. Charman. 8/19/2004. "Identification of an antimalarial synthetic trioxolane drug development candidate." Nature 430: 7002: 900-904. 10.1038/nature02779.

Wikipedia Citation

<ref> {{Cite journal | doi = 10.1038/nature02779 | issn = 1476-4687 | volume = 430 | pages = 900-904 | last = Vennerstrom | first = Jonathan L. | coauthors = Arbe-Barnes, Sarah, Brun, Reto, Charman, Susan A., Chiu, Francis C. K., Chollet, Jacques, Dong, Yuxiang, Dorn, Arnulf, Hunziker, Daniel, Matile, Hugues, McIntosh, Kylie, Padmanilayam, Maniyan, Santo Tomas, Josefina, Scheurer, Christian, Scorneaux, Bernard, Tang, Yuanqing, Urwyler, Heinrich, Wittlin, Sergio, Charman, William N. | title = Identification of an antimalarial synthetic trioxolane drug development candidate | journal = Nature | date = 8/19/2004 | pmid = | pmc = }} </ref>